Cardiac mesenchymal cells from failing and nonfailing hearts limit ventricular dilation when administered late after infarction.

ABSTRACT: Although cell therapy-mediated cardiac repair offers promise for treatment/management of heart failure, lack of fundamental understanding of how cell therapy works limits its translational potential. In particular, whether reparative cells from failing hearts differ from cells derived from nonfailing hearts remains unexplored. Here, we assessed differences between cardiac mesenchymal cells (CMC) derived from failing (HF) versus nonfailing (Sham) hearts and whether the source of donor cells (i.e., from HF vs. Sham) limits reparative capacity, particularly when administered late after infarction. To determine the impact of the donor source of CMCs, we characterized the transcriptional profile of CMCs isolated from sham (Sham-CMC) and failing (HF-CMC) hearts. RNA-seq analysis revealed unique

SUBMITTER: Audam TN 

PROVIDER: S-EPMC7474443 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature